



General Practice Notebook – a UK medical reference

27,000 index terms

2.5 million words



“GPnotebook – From Input to Output...Origins,
GPnotebook and GPnotebook Education”
Jim McMorran Editor-in-Chief GPnotebook

Introducing



*a clinical encyclopaedia
on the World Wide Web*

28000 pages 66000 links 100000 users

[Home](#)

[About us](#)

[Contact us](#)

[Authors](#)

[Help](#)

[FAQ](#)

[News & Testimonials](#)

[Advertise with us](#)



welcome

Medical search



GPnotebook is an online encyclopaedia of medicine that provides a trusted immediate reference resource for clinicians in the UK and internationally. Updated continually, our database consists of over 26,000 pages of information. Fast and reliable, many doctors use GPnotebook during the consultation. To browse a clinical chapter just click on a heading to the right. If you know what you are looking for then use the power of our search engine by typing your request into the medical search box. If you have any comments or criticisms please do not hesitate to contact us.

[about GPnotebook](#)
[orthopaedics](#)
[cardiovascular \(CV\) medicine](#)
[chest medicine](#)
[dermatology](#)
[ear, nose and throat](#)
[endocrinology](#)
[evidence-based medicine](#)
[gastroenterology](#)
[general information](#)
[general practice](#)
[geriatric medicine](#)
[guidelines section](#)
[gynaecology](#)
[infectious disease](#)

[haematology](#)
[musculoskeletal medicine](#)
[neurology](#)
[obstetrics](#)
[oncology](#)
[ophthalmology](#)
[paediatrics](#)
[palliative care](#)
[rheumatology](#)
[psychiatry](#)
[public health](#)
[renal medicine](#)
[surgery](#)
[trauma medicine](#)
[GPnotebook educational module \(GEMs\)](#)

univadis
a service from 

...or join now to receive:

Congress Highlights

FREE ACCESS
to GPnotebook today

[Join now](#)

This site is intended for healthcare professionals

Not just another LAMA/LABA



SPIOLTO
RESPIMAT[®]

[Prescribing information, adverse event reporting, refs](#) Intended for UK healthcare professionals only Boehringer Ingelheim Ltd UK/SPRES-181356 Aug 18



univadis[®]

Stay one step ahead
in just minutes a day



REGISTER
NOW

[Account login](#) | [New account](#)

[Home](#)

[About](#) ▾

[Education](#)

[GPnotebook Round-Up](#)

[MCQs](#)

[Contact us](#)

Medical search

Enter Your Search Here



Welcome

GPnotebook provides a trusted, immediate reference resource for clinicians in the UK and internationally. Updated continually to incorporate new advances and guidelines as they appear, our database consists of over 27,000 pages of information. Fast and reliable,

Search categories

- [Cardiovascular medicine](#)
- [Dermatology](#)
- [Diabetes and endocrinology](#)
- [Ear, nose and throat](#)
- [Evidence-based medicine](#)
- [Gastroenterology](#)
- [General information](#)
- [General practice](#)
- [Geriatric medicine](#)
- [Gynaecology](#)
- [Haematology](#)
- [Infectious disease](#)
- [Musculoskeletal medicine](#)



[Prescribing information, adverse event reporting, refs](#) Intended for UK healthcare professionals only Boehringer Ingelheim Ltd UK/SPRES-181357 Aug 18



[Br J Gen Pract](#). 2014 Feb; 64(619): 92–93.

doi: [\[10.3399/bjgp14X677202\]](#)

PMCID: PMC3905431

PMID: [24567602](#)

20 years of GPnotebook: from a medical student project to a national resource

[James McMorran](#), Coventry GP

GPwSI in Diabetes and Cardiovascular Risk, Coventry and Rugby CCG; Honorary Clinical Associate Professor, Warwick University, Coventry. Editor and co-creator of GPnotebook.

[Damian Crowther](#)

University of Cambridge, Department of Genetics, Cambridge.

[Stewart McMorran](#)

Consultant in Accident and Emergency Medicine and Clinical Director Buckingham Hospitals NHS Trust, Amersham.

Formats:

Article | [PubReader](#) | [ePub \(beta\)](#) | [PDF \(37K\)](#) | [Citation](#)

Share

[Facebook](#) [Twitter](#) [Google+](#)

Save items

★ Add to Favorites ▼

Similar articles in PubMed

History matters for understanding knowledge exchange.

[Milbank Q. 2010]

[The "caged brain"].

[J Neuroradiol. 2002]

[100 years of Nobel Prizes for Medicine].

[Rev Med Chir Soc Med Nat Iasi...]

The internet and the physician-patient relationship.

[Clin Orthop Relat Res. 2010]

A tale of two books.


[Cardiol Young. 2010]

**“I was an overnight success
all right, but 30 years is a
long, long night.”**

— Ray Kroc

**1989 Medical Student
Merton College (Tolkein's
College)
Oxford University**

- Pre-Clinical Advisor's Scholarship – ranked 1st out of > 100 graduate applicants (Maths)
- Paulo Coelho's – The Alchemist
- “The world as we have created it is a process of our thinking. It cannot be changed without changing our thinking.”
— Albert Einstein




“Any fool can know. The point is to understand.”


— Albert Einstein


1990 – JRH Canteen

John Radcliffe Hospital site map



“Medical Knowledge is concomitant and not sequential...medical textbooks are sequential and two dimensional...medical knowledge needs to be represented concomitantly and so in a three dimensional decision space...”





Blues Brothers

Stewart – Cambridge “Blue”
Jim – Oxford “Blue”



[Br J Gen Pract](#). 2014 Feb; 64(619): 92–93.


James discussed with Stewart McMorran (then a medical student at Cambridge University and a talented computer programmer) this way of representing medical knowledge and between them they created the authoring software to produce linking ‘packets’ of information in a database. This first authoring software and database was the origin of what today is GPnotebook... **It was, in effect, a ‘Wiki’ over 16 years before the first ‘Wiki’!**

**“Logic will get you from A to Z;
imagination will get you
everywhere ...”**

**“I have no special talent. I am
only passionately curious...”**

— Albert Einstein

INPUT INPUT...




Teamwork...The Paper Chase...



**“Never memorize something
that you can look up.”**

— Albert Einstein

The Team..."This has never been done before..."




John Pleat



Stewart McMorran



Steven Young-Min



Damian Crowther




Ian Wacogne



Jim McMorran

1991 – team or individual...



The Team evolves...



John Pleat



Damian Crowther



Stewart McMorran



Ian Wacogne



Steven Young-Min



Jim McMorran



Clive Prince

John Perry Prize 1992

Personalised Medical Reference

A Computerised Aide Memoire for General Practitioners

Stewart McMorran, Cambridge University Medical School
Dr. Clive Prince, Bewdley Medical Centre

Abstract

General Practice is changing. Administration, costings and quality of care are becoming more tightly regulated. Many practices are looking to the computer for assistance.

The greater uptake of computers provides a convenient platform for their use in other capacities. We have developed a flexible, dynamic, up-dateable and structured computerised medical reference system to make information available to the physician within the consultation. Accessed from within the patient record, Personalised Medical Reference (PMR) provides up-to-date information on diseases and conditions encountered both routinely and infrequently in General Practice. PMR can serve both as an aide-memoire and as a channel for conveying current medical thinking. It can also be extended to incorporate local information with additions transferred automatically to successive editions as updates are released.

the doctor to treat patients which at one time, might have been referred to specialists.


Introduction

The face of General Practice is changing. Increasingly, general practitioners will be administered as a capitation system. The computer will feature more prominently to record transactions and to perform audit whilst also, providing the opportunity for use in other capacities.

General practitioners work in a time constrained environment. Within 6 minutes or less, the physician is expected to identify the cause of the patient's complaint, decide upon a suitable treatment, explain it to the patient, and make a record of the interaction.

Since their widespread introduction in the mid-1980's, computers have provided an opportunity to assist the doctor in this role. The patient's record and assistance with drug prescribing, protocol management etc. are a

1994



1994

**Demonstration
Disks Available
from Head Office**

D
M BCh (Oxon)

not
d can be
ipulate
d speed

k for
ich make

n,
ical
viewed
sicians

r target

m and
lties,
nd across

MEDILINKS

**LIFETIME
INDIVIDUAL
NOTES AND
KNOWLEDGE
SYSTEM**


James Mc Morran
Stewart Mc Morran
Steven young Min
Ian Wacogne
Carl Rowbothom
Damian Crowther
Jon Pleat

**A MEDICAL TEXTBOOK
FOR LIFE**

BUTTERWORTH-HEINEMANN

- **IBM-compatible PC required**
- **Available for two operating systems: MS-DOS or Windows**

READERSHIP: Undergraduate medical students, junior hospital doctors, nursing staff, allied healthcare professionals



LIFETIME
INDIVIDUALIZED
NOTES &
KNOWLEDGE
SYSTEM

James McMorran
Stewart McMorran
Ian Wacogne
Damian Crowther
Jon Pleat
Steven Young-Min
Carl Rowbotham

LIFETIME
MEDICAL
REFERENCE

LIFETIME INDIVIDUALIZED NOTES & KNOWLEDGE SYSTEM

James McMorran BM, BCh, BS, MS, PhD
Stewart McMorran BM, BCh, BA, BS, MS, MPhil
Ian Wacogne BM, BCh, BA
Damian Crowther MA, PhD, BM
Jon Pleat BA, BM
Steven Young-Min BM, BCh, BA
Carl Rowbotham BM, BCh, MA

MEDLINKS - A Lifetime Medical Reference is a comprehensive reference system containing the core of accepted medical information. Based on the medical curriculum it contains all traditional hospital specialties, linking clinical information within and across those specialties.

MEDLINKS functions along three axes from knowledge, symptomatic and pathology. It also uses semantic indexes e.g. 'may be caused by' and 'may cause' to give flexible and rapid access to over 11,000 separate clinical entities and over one million words.

By allowing users to add their own notes anywhere in the text or specifically in their own specialty, and by also allowing these notes to be incorporated into regular updates, this truly becomes a Lifetime Medical Reference, accompanying users throughout their medical careers.

Hardware Requirements

Windows version:

- 386 or higher IBM compatible
- Windows 3.1 or later
- 3.5 inch floppy disk drive
- Hard disk with 20 MB free space
- 2 MB RAM
- Any printer supported by Windows



BUTTERWORTH
HEINEMANN

“You never fail until you stop trying.”

— Albert Einstein

1996-2000

- No second edition of Medilinks
- Various “false starts” ...ePulse, National Electronic Library for Health...
- Continued to keep up to date – Damian became the technical lead for the database and learnt how to program in ColdFusion, mySQL, visualBasic and Java Script
- All progressing with our respective medical careers

2001 – “stick or twist”

- Google and www had become predominant
- Scott Moses “FPnotebook”
- GPnotebook – logo based on faxes (Brandon Road and Cambridge) between Damian and I in September 2001
- GPnotebook “led” by Damian and myself...
- First day on www 32 “hits” then ...

November 2018

- 17,291 GMC accredited GPs accessed GPnotebook via either Univadis or their own purchased login – **approximately 50% of UK GPs signed into GPnotebook in November 2018**

Articles

Personalised Medical Reference to General Practice Notebook (GPnotebook) – an evolutionary tale

James McMorran BM BCh PhD DCH DRCOG MRCP

General Practitioner, Coventry, and Visiting Senior Clinical Lecturer, Centre for Primary Health Care Studies, Warwick University, Warwickshire, UK

Damian Crowther MA BM BCh PhD MRCP

Honorary Registrar in Neurology, Addenbrooke's NHS Trust, and Wellcome Advanced Training Fellow, Cambridge Institute for Medical Research, Cambridge, UK

This article describes GPnotebook, the winner of the 2002 John Perry Prize, awarded annually by the PHCSG in memory of Dr John Perry, for outstanding innovation in primary care informatics.

ABSTRACT

In 1992, a group of medical students and a UK general practitioner were awarded the John Perry Prize for an MS-DOS-based flexible, dynamic, updateable and structured computerised medical reference system. At the time of the award the reference system contained over 4000 index terms and was designed to provide an easy-to-retrieve synopsis of the whole of clinical medicine.

What has happened to this resource now? This brief paper outlines how the developers of the reference resource have improved on the design and

content of the medical database. Now the reference resource is an Internet-based resource called General Practice Notebook (www.gpnotebook.co.uk) and is currently attracting 5000 to 9000 page views per day and containing over 30 000 index terms in a complex web structure of over 60 000 links. This paper describes the evolutionary process that has occurred over the last decade.

Keywords: database, Internet-based resource, reference system



hdl phenytoin

All Images Shopping News Videos More Settings Tools

About 187,000 results (0.34 seconds)

Effects of phenytoin on plasma high-density lipoprotein cholesterol ...

<https://www.ncbi.nlm.nih.gov/pubmed/8522632>

by C Goerdts - 1995 - Cited by 21 - Related articles

Effects of **phenytoin** on plasma high-density lipoprotein cholesterol levels in men with low levels of high-density lipoprotein cholesterol. ... A low level of high-density lipoprotein cholesterol (HDL-C) is an important and new risk factor for coronary heart disease.

HDL and phenytoin - General Practice Notebook

<https://www.gpnotebook.co.uk/simplepage.cfm?ID=x20100908150948755037>

HDL and **phenytoin**. The effects of different anticonvulsant drugs on lipid profiles is inconsistent between studies. However there is a reasonable evidence base suggesting that **HDL** levels may be raised with **phenytoin** therapy. Also carbamazepine seems to increase total cholesterol and **HDL** levels.

A Prospective, Randomized Trial of Phenytoin in Nonepileptic ...

<https://www.ahajournals.org/doi/abs/10.1161/01.atv.15.12.2151>

by M Miller - 1995 - Cited by 28 - Related articles

Abstract Observational studies have demonstrated a positive association between **phenytoin** use and **HDL** cholesterol (HDL-C). Our goal was to determine ...

Phenytoin treatment reduces atherosclerosis in mice through ...

[www.atherosclerosis-journal.com/article/S0021-9150\(04\)00131-5/abstract](http://www.atherosclerosis-journal.com/article/S0021-9150(04)00131-5/abstract)

by C Trocho - 2004 - Cited by 10 - Related articles

Phenytoin (PHT) increases high density lipoprotein cholesterol (HDL-C) and reduces coronary artery disease mortality in humans. We report the results of PHT ...



comparison conjunctivitis iritis glaucoma



All

Images

News

Shopping

Videos

More

Settings

Tools

About 208,000 results (0.42 seconds)

Conjunctivitis is a common patient complaint. It is the most likely diagnosis in a patient with a red eye and discharge. ... In contrast to acute **conjunctivitis**, these entities, such as acute angle closure **glaucoma**, **iritis**, and infectious keratitis, must be managed by ophthalmologists and will not be discussed here. 26 Nov 2018

[Conjunctivitis - UpToDate](https://www.uptodate.com/contents/conjunctivitis)

<https://www.uptodate.com/contents/conjunctivitis>

About this result Feedback

People also ask

How do you get rid of a styne overnight?

What causes red eyes and swollen eyelids?

Is scleritis a form of uveitis?

Does blepharitis go away?

[Feedback](#)

[\[PDF\] Red Eye Presentation](#)



comparison conjunctivitis iritis glaucoma



What causes red eyes and swollen eyelids? ▾

Is scleritis a form of uveitis? ▾

Does blepharitis go away? ▾

[Feedback](#)

[\[PDF\] Red Eye Presentation](#)

<https://med.virginia.edu/ophthalmology/wp-content/uploads/sites/.../RedEyePPT.pdf> ▾

Angle-closure **glaucoma**. 3. Ocular foreign body. 4. Corneal abrasion. 5. **Uveitis**. 6. **Conjunctivitis**. 7. Ocular surface disease. 8. Subconjunctival hemorrhage.

[acute glaucoma\(comparison with iritis and conjunctivitis\) - General ...](#)

<https://www.gpnotebook.co.uk/simplepage.cfm?ID=-1435828217> ▾


degree of pain, photophobia, discharge, redness, cornea, pupil, intraocular pressure. acute **conjunctivitis**, roughness on lid movements, slight photophobia, clear ...

[Causes, complications and treatment of a red eye - BPJ Issue 54](#)


<https://bpac.org.nz/bpj/2013/august/redeye.aspx> ▾

Causes, complications and treatment of a red eye. Most cases of "red eye" seen in general practice are likely to be **conjunctivitis** or a superficial corneal injury, however, red eye can also indicate a serious eye condition such as acute angle **glaucoma**, **iritis**, keratitis or scleritis.


The most common search terms




Broad distribution of search term frequencies




The most frequently visited pages



Visits peak during surgery times on weekdays



Personal Knowledge Graphs





The pages edited by Jim are:

If you want a list of pages deleted by this author then [click here](#)

Record	Title of page	Date	View Previous
1	surgical treatment related to voiding symptoms associated with benign prostatic enlargement	23/12/2018	view previous
2	prostate artery embolisation (PAE) for lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH)	23/12/2018	N/A
3	prostate artery embolisation (PAE) for lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH)	23/12/2018	view previous
4	prostate artery embolisation (PAE) for lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH)	23/12/2018	N/A
5	NICE guidance - insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia	23/12/2018	view previous
6	BPH	23/12/2018	view previous
7	urolift procedure (prostatic urethral lift)	23/12/2018	view previous
8	urolift procedure (prostatic urethral lift)	23/12/2018	N/A
9	urolift procedure (prostatic urethral lift)	23/12/2018	view previous
10	urolift procedure (prostatic urethral lift)	23/12/2018	view previous
11	urolift procedure (prostatic urethral lift)	23/12/2018	N/A
12	transurethral resection of prostate	23/12/2018	N/A
13	treatment of benign prostatic hyperplasia	23/12/2018	view previous
14	Transurethral resection of prostate and laser prostatectomy	23/12/2018	N/A
15	transurethral resection of prostate	23/12/2018	view previous
16	UTI in a woman	21/12/2018	N/A

File Edit View History Bookmarks Tools Help

List of changes for Jim

www.gpnotebook.co.uk/changeList.cfm

Most Visited Getting Started New Tab http://www.barfordpla... https://www.youtube.c... Find Us - University H... iPad Suggested Sites General Practice Note...

27816	MAST questionnaire	12/12/2002	view previous	text update
27817	tamoxifen	05/12/2002	view previous	text update
27818	efamast (R)	05/12/2002	view previous	text update
27819	evening primrose oil	05/12/2002	view previous	text update
27820	ovarian cancer and hormone replacement therapy (HRT)	05/12/2002	view previous	text update
27821	ovarian cancer and hormone replacement therapy (HRT)	05/12/2002	N/A	new page
27822	tamoxifen and risk of DVT / PE	05/12/2002	view previous	text update
27823	tamoxifen	05/12/2002	view previous	text update
27824	tamoxifen and venous thromboembolism	05/12/2002	N/A	new page
27825	tamoxifen	05/12/2002	view previous	text update
27826	contraindications	05/12/2002	view previous	text update
27827	Dianette and risk of DVT and/or PE	04/12/2002	view previous	text update
27828	Dianette and risk of DVT and/or PE	04/12/2002	N/A	new page
27829	Dianette (R)	04/12/2002	view previous	text update
27830	myalgia and myositis associated with statin treatment	04/12/2002	view previous	text update
27831	checklist before BCG vaccination	03/12/2002	view previous	text update
27832	checklist before BCG vaccination	03/12/2002	view previous	text update
27833		03/12/2002	view	

Type here to search

14:54 23/12/2018



This site is intended for healthcare professionals

Intended for healthcare professionals. [Click here for prescribing information and adverse event reporting](#)

NVA F = Non-Valvular Atrial Fibrillation
 Reference: 1. Granger CB et al. N Engl J Med 2011; 365: 983-992.
 DoP: Sept 2018 Job code: 432UK1800798-01
 For more details visit www.eliqis.co.uk




univadis[®] 

Learn from experts and peers [REGISTER NOW](#)

[Profile page](#) | [Logout](#)

- [Home](#)
- [About ▾](#)
- [Education](#)
- [GPnotebook Round-Up MCQs](#)
- [Contact us](#)
- [Your details](#)
- [Tracked pages ▾](#)
- [Apps ▾](#)

Medical search


Enter Your Search Here

Welcome

GPnotebook provides a trusted, immediate reference resource for clinicians in the UK and internationally. Updated continually to incorporate new advances and guidelines as they appear, our database consists of over 27,000 pages of information. Fast and reliable, many doctors use GPnotebook during the

Search categories

- Cardiovascular medicine**
- Dermatology**
- Diabetes and endocrinology**
- Ear, nose and throat**
- Evidence-based medicine**
- Gastroenterology**
- General information**
- General practice**
- Geriatric medicine**
- Gynaecology**
- Haematology**
- Infectious disease**
- Musculoskeletal medicine**



GPnotebook Clinics

A new series of primary care update courses launching across the UK and Ireland for all primary care professionals.

Free from pharmaceutical sponsorship or exhibitors

Book now for your special introductory offer for 2019

To view the dates, locations and agenda [CLICK HERE](#)

A one day course with up to 6 hours of CPE points

Eliquis
apixaban

Superiority on the prevention stroke / systemic embolism vs. wa

Prevention of stroke / systemic embolism in patients with NAF

Intended for healthcare professionals.
Click here for prescribing information and adverse event reporting
NAF = Non-Valvular Atrial Fibrillation
Reference: 1. Granger CB et al. N Engl J Med 2011; 365: 981-992.
DoP: Sept. 2018 Job code: 432UK1800798-01
For more details visit www.eliquis.co.uk



univadis[®]

Free and unlimited access to GPnotebook

REGISTER NOW

[Profile page](#) | [Logout](#)

- Home
- About ▾
- Education
- GPnotebook Round-Up
- MCQs
- Contact us

- Your details
- Tracked pages ▾
- Apps ▾

Medical search

Enter Your Search Here

Emails

Please choose your email.

-- Emails --

Superiority on the prevention of stroke / systemic embolism vs. warfarin¹

Eliquis
apixaban

Prevention of stroke / systemic embolism in patients with NAF
Intended for healthcare professionals.
Click here for prescribing information and adverse event reporting
NAF = Non-Valvular Atrial Fibrillation
Reference: 1. Granger CB et al. N Engl J Med 2011; 365: 981-992.
DoP: September 2018 Job code: 432UK1800914-01
For more details visit www.eliquis.co.uk



univadis®



Stay one step ahead
in just minutes a day

REGISTER
NOW

[Profile page](#) | [Logout](#)

[Home](#)

[About ▾](#)

[Education](#)

[GPnotebook Round-Up
MCQs](#)

[Contact us](#)

[Your details](#)

[Tracked pages ▾](#)

[Apps ▾](#)

Medical search



Emails

Please choose your email.

-- Emails --

-- Emails --

Email "Round Up" Series 9

Round Up Email January 2019

Prevention of stroke / systemic embolism in patients with NVAf
Intended for healthcare professionals.
[Click here for prescribing information and adverse event reporting](#)
NVAf = Non-Valvular Atrial Fibrillation
Reference: 1. Granger CB et al. N Engl J Med 2011; 365: 981-992.
DoP: September 2018 Job code: 432UK1800914-01
For more details visit www.eliquis.co.uk

Education

GPnotebook Round-Up
MCQs

Contact us

Your details

Tracked pages ▼

Apps ▼

Emails

Please choose your email.

Round Up Email January 2019



[Download email in PDF version](#)

Round Up Email January 2019

Dear GPnotebook Users, Evidence and Guidance changes – and GPs need to be aware of these as some can lead to significant changes in how we undertake our role. The GPnotebook Round Up series seeks to reflect and highlight these to make the job of GPs easier. In this month's "Round Up" email highlights include:

[Update in management of vitamin D insufficiency based on the National Osteoporosis Society guidance from December 2018](#)

1) Which statement regarding management of vitamin D deficiency is false?

1) Which statement regarding management of vitamin D deficiency is false?

- serum vitamin D (25OHD) of 30-50 nmol/L may be inadequate in some people
- NOS recommend checking adjusted serum calcium 1 week after completing the loading regimen or after starting vitamin D supplementation in case primary hyperparathyroidism has been unmasked
- oral vitamin D3 (colecalciferol) is the treatment of choice in vitamin D deficiency

NICE COPD guidance from December 2018 states for the first-time states when antibiotic prophylaxis should be used and what investigations need to be undertaken before antibiotic prophylaxis can be started

2) Which statement regarding antibiotic prophylaxis in COPD is false?

- Baseline liver function tests are required before long term azithromycin therapy
- Patients should be advised of possible tinnitus secondary to azithromycin therapy
- Baseline echocardiogram is advised before commencing azithromycin therapy

D-mannose for the prevention of recurrent UTIs. What is the evidence for this? Is this NICE approved?

3) Which statement regarding use of D-mannose for prevention of UTIs is true?

- Several fruits and vegetables contain D-mannose, including apples
- NICE advise against non pregnant women using D-mannose to reduce risk of recurrent UTIs
- D-mannose can be transformed into glycogen, therefore can be stored in the body

Catheter Associated UTI – what is the management of this condition. GPnotebook combines SIGN and NICE guidance to give a “key facts” guide to management.

4) Which statement regarding catheter associated UTI is true?

- first choice oral antibiotic if upper UTI symptoms is nitrofurantoin
- second choice oral antibiotic if no upper UTI symptoms is trimethoprim
- do not treat catheterised patients with asymptomatic bacteriuria with an antibiotic

A 40-year-old presenting with hyperglycaemia and osmotic symptoms – could this be type 1 or type 2 diabetes?

5) Which statement is not suggestive of a diagnosis of type 1 diabetes?

- Raised C-peptide levels
- ketonaemia ≥ 3 mmol/l on capillary testing or ketonuria
- normal or low body weight or rapid weight loss

Clinical Rarity – a clinic letter stated that chronic pancreatitis was due to IgG4 disease – what is this condition?

6) Which statement regarding IgG4 disease is true?

- IgG4 disease is associated with alcohol excess
- IgG4 disease may be associated with sclerosing cholangitis
- IgG4 disease causes only a focal autoimmune pancreatitis



[Home](#)

[About](#) ▼

[Education](#)

[GPnotebook Round-Up
MCQs](#)

[Contact us](#)

[Your details](#)

[Tracked pages](#) ▼

[Apps](#) ▼

[Medical search](#)

Enter Your Search Here



MCQs results

Question "1) Which statement regarding management of vitamin D deficiency is false?" has been answered incorrectly

5 / 6 correct

[Take Quiz again](#)

May use questions as a prompt for other learning...

1) Which statement regarding management of vitamin D deficiency is false?

- serum vitamin D (25OHD) of 30-50 nmol/L may be inadequate in some people
- NOS recommend checking adjusted serum calcium 1 week after completing the loading regimen or after starting vitamin D supplementation in case primary hyperparathyroidism has been unmasked
- oral vitamin D3 (colecalciferol) is the treatment of choice in vitamin D deficiency

NICE COPD guidance from December 2018 states for the first-time states when antibiotic prophylaxis should be used and what investigations need to be undertaken before antibiotic prophylaxis can be started

2) Which statement regarding antibiotic prophylaxis in COPD is false?

- Baseline liver function tests are required before long term azithromycin therapy
- Patients should be advised of possible tinnitus secondary to azithromycin therapy
- Baseline echocardiogram is advised before commencing azithromycin therapy

1) When is vit D 30-50 nmol/l inadequate?

2) Is a pulsed prophylaxis antibiotic regime more effective than daily antibiotics?

When is vit D 30-50 nmol/l inadequate?

Apps ▾

[Download email in PDF version](#)

Round Up Email January 2019

Dear GPnotebook Users, Evidence and Guidance changes – and GPs need to be aware of these as some can lead to significant changes in how we undertake our role. The GPnotebook Round Up series seeks to reflect and highlight these to make the job of GPs easier. In this month's "Round Up" email highlights include:

[Update in management of vitamin D insufficiency based on the National Osteoporosis Society guidance from December 2018](#)

1) Which statement regarding management of vitamin D deficiency is false?

- serum vitamin D (25OHD) of 30-50 nmol/L may be inadequate in some people
- NOS recommend checking adjusted serum calcium 1 week after completing the

When is vit D 30-50 nmol/l inadequate?

- 25OHD > 50 nmol/L is sufficient for almost the whole population
- **treatment thresholds (1):**
 - **Serum 25OHD < 30 nmol/L:** treatment recommended
 - **Serum 25OHD 30-50 nmol/L:** treatment is advised in patients with the following:
 - fragility fracture, documented osteoporosis or high fracture risk
 - treatment with antiresorptive medication for bone disease
 - symptoms suggestive of vitamin D deficiency
 - increased risk of developing vitamin D deficiency in the future because of reduced exposure to sunlight, religious/cultural dress code, dark skin, etc.
 - raised PTH
 - medication with antiepileptic drugs or oral glucocorticoids
 - conditions associated with malabsorption
 - **serum 25OHD > 50 nmol/L:** provide reassurance and give advice on maintaining adequate vitamin D levels through safe sunlight exposure and diet

Is a pulsed prophylaxis antibiotic regime more effective than daily antibiotics?

- **implications for practice**

- "...use of prophylactic macrolide antibiotics for a period of up to 12 months is likely to reduce the number of patients with one or more exacerbations, exacerbation frequency, increase the median time to first exacerbation and improve health-related quality of life. **Benefits appear to be driven by continuous and intermittent macrolide regimens, with pulsed regimens being less effective.**" (1)

- antibiotic regimes (1):

- example adult regimes used in clinical trials include:
 - Azithromycin 250 mg daily or
 - Azithromycin 250 mg 3 times a week

[Home](#)

[About ▼](#)

[Education](#)

[GPnotebook Round-Up
MCQs](#)

[Contact us](#)

[Your details](#)

[Tracked pages ▲](#)

[In chronological order](#)

[Reflective notes](#)

[Your PKG](#)

[Annotations](#)

[CPD diary](#)

[Apps ▼](#)

Medical search

Enter Your Search Here



Pages read in GPnotebook.co.uk

Select start of report:

20



Jan



2018



Select end of report:

20



Jan



2019



Display Report



[Click for help with your
tracker statements](#)

Pages tracked:

EMPA - REG trial - empagliflozin in type 2 diabetes patients with high cardiovascular risk (EMPAREG)

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial

SUSTAIN - 6

DECLARE - TIMI 58 - dapagliflozin and cardiovascular outcomes in type 2 diabetes

CANVAS Program - Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

- clinical features
- treatment and prevention

slapped cheek disease

10/01/2019

Pages tracked:

cortical bone island

09/01/2019

Pages tracked:

trials with respect to lipid lowering

evolocumab and clinical outcomes in patients with cardiovascular disease

pharyngeal cancers

27/12/2018

Pages tracked:

REDUCE - IT

- age and prognosis for breast cancer
- prognosis

breast cancer

staging of breast carcinoma (stage I -IV)

- age and prognosis for breast cancer
- prognosis

staging of breast carcinoma (stage I -IV)


- prognosis

breast cancer

- one, five and ten year survival statistics
- prognosis according to stage of disease
- prognosis
- one, five and ten year survival statistics
- prognosis according to stage of disease
- prognosis

lung cancer






Your personal PKG breakdown



Your personal PKG breakdown



- Cardiovascular medicine ■ Respiratory and chest medicine ■ dermatology
- Ear, nose and throat ■ diabetes and endocrinology ■ gastroenterology ■ geriatric medicine
- gynaecology ■ infectious disease ■ musculoskeletal medicine ■ neurology ■ obstetrics
- oncology ■ ophthalmology ■ paediatrics ■ palliative care ■ rheumatology ■ psychiatry
- renal medicine ■ surgery ■ trauma medicine



[Home](#)

[About ▾](#)

[Education](#)

[GPnotebook Round-Up
MCQs](#)

[Contact us](#)

[Your details](#)

[Tracked pages ▲](#)

[In chronological order](#)

[Reflective notes](#)

[Your PKG](#)

[Annotations](#)

[CPD diary](#)

Medical search

Enter Your Search Here



CPD diary

for Jim McMorran

20 Jan 2019

[Back to content](#)

Today this page is a:

DEN (Doctor's Educational Need)

PUN (Patient's Unmet Need)

[Assign](#)

Your PKG

Annotations

CPD diary

Apps ▼



Doctor's educational needs (DENS)

1) proteinuria

(assigned as a DEN on: 26/04/2018)

2) cancer (larynx)

(assigned as a DEN on: 27/12/2018)

Annotation linked to this page:

1) *Update of prognosis*: Updated knowledge of prognosis of laryngeal cancer

3) rhabdomyolysis associated with statin treatment

(assigned as a DEN on: 13/07/2018)

4) Ehlers Danlos syndrome

(assigned as a DEN on: 08/06/2018, 13/06/2018)

5) prognosis of laryngeal cancer

(assigned as a DEN on: 27/12/2018)

6) DOAC - monitoring

Home

About ▼

Education

GPnotebook Round-Up
MCQs

Contact us

Your details

Tracked pages ▼

Apps ▼

Printer friendly

Medical search

Enter Your Search Here



GEM - cancer educational module

Cancer

- the GP role extends from primary prevention through early diagnosis of cancer to terminal care, and so for family doctors cancer needs to be seen as a patient journey in which they are involved at various stages (1)
- cancer is principally a disease of ageing, and in an ageing population it is becoming more common: 65 percent of all new cancers occur in people over 65 years. During 2000, 270,000 new cases of cancer were registered in the UK (1):
 - over half of these were from the breast, lung, colon and prostate
 - in 2002, cancer accounted for 26 percent of all mortality in the UK, 155,180 deaths - now greater than heart disease
 - of cancer deaths, lung cancer was responsible for 22 percent and is the biggest cause in both sexes
 - cigarette smoking is the single most important cause for lung cancer and may be linked to one-third of all cancer deaths
 - for patients under 65, cancer kills 37 percent; for women under 65 this

- cancer and may be linked to one third of all cancer deaths
- for patients under 65, cancer kills 37 percent; for women under 65 this figure rises to 47 percent
- cancer is a clear concern for many patients who consult their doctor and it is, a concern driven by common life experience

With respect to the epidemiology of cancer:

- regarding aetiological risk factors for development lung cancer:
 - how does passive smoking affect risk of lung cancer?
 - which type of asbestos exposure is principally associated with risk of mesothelioma?
 - is nickel exposure associated with risk of lung cancer?
 - **GPN reference**
- regarding risk factors for development of breast cancer:
 - what is the lifetime risk of breast cancer associated BRCA1 gene?
 - **GPN reference**
 - what are the referral criteria from primary care regarding a family history of breast cancer?
 - **GPN reference**
 - how does HRT usage affect the risk of breast cancer development?
 - **GPN reference**
- regarding risk factors for development of ovarian cancer:
 - how does family history affect the risk of ovarian cancer?
 - **GPN reference**

criteria for referral to secondary care (familial breast cancer)

- **Offer referral to secondary care for breast cancer risk estimation if the person meets any of the following criteria:**
 - **One first degree female relative with breast cancer at <40 years of age or**
 - **One first degree male relative with breast cancer at any age or**
 - **One first degree relative with bilateral breast cancer where the first primary was diagnosed at <50 years of age or**
 - **Two first degree relatives, or one first degree plus one second degree relative, with breast cancer at any age or**
 - **One first degree or second degree relative with breast cancer at any age plus one first degree or second degree relative with ovarian cancer at any age (one of these should be a first degree relative) or**
 - **Three first degree or second degree relatives on the same side**

- **One first degree or second degree relative with breast cancer at any age plus one first degree or second degree relative with ovarian cancer at any age (one of these should be a first degree relative) or**
 - **Three first degree or second degree relatives on the same side of the family with breast cancer at any age**
- Women who do not meet these criteria can be reassured that they are at near population risk of getting breast cancer and do not require referral for specific breast cancer risk estimation.

Breast cancer risk category

	Near population risk	Moderate risk	High Risk *
Lifetime risk from age 20	Less than 17%	Greater than 17% but less than 30%	30% or greater
Risk between ages 40 and 50	Less than 3%	3-8%	Greater than 8%

*This group includes known BRCA1, BRCA2 and TP53 mutations and rare conditions that carry an increased risk of breast cancer such as Peutz-Jegher syndrome (STK11), Cowden (PTEN) and familial diffuse gastric cancer (E-Cadherin)

- **Surveillance for women with no personal history of breast cancer**
 - **Offer annual mammographic surveillance to women:**
 - aged 40-49 years at moderate risk of breast cancer



GP notebook Clinics



GPnotebook Clinics: Half-day event



A typical “Clinic” will mirror our daily work in primary care and use multiple patient case studies to cover the latest clinical guidance, research and hot topics (e.g. SIGN 154 Diabetes 2017 and NICE NG106 Heart Failure September 2018).

Case studies will also include diagnosis and management pearls for more common presentations (e.g. dermatology and musculoskeletal complaints), prescribing & de-prescribing (including drug safety alerts) and also the interpretation of commonly abnormal investigations such as blood tests and spirometry.

Finally, a “Home Visits” section will focus on the management of multi morbidity, frailty and polypharmacy in primary care.

09:00 – 09:30 [Registration and coffee](#)

09:30 – 09:45 [Introduction](#)

- Overview of meeting, website, resources and workbook

[Session 1: Morning clinic](#)

09:45 – 11:10 [Patient case scenarios](#)

- Patient case studies to cover the latest clinical guidelines, research and hot topics relevant to primary care
- “Back to Basics” – diagnostic & management pearls for commonly encountered conditions & situations in primary care e.g. MSK and dermatology

11:10 – 11:30 [Coffee Room chat](#)

[Session 2: Clinic admin](#)

11:30 – 11:50 [“Docman” inbox](#)

- The management of commonly abnormal blood tests
- Interpretation of abnormal investigations such as ECGs and spirometry

11:50 – 12:05 [Telephone consultation and triage](#)

- Practical management tips and common pitfalls including case scenarios

12:05 – 12:25 [Prescribing and de-prescribing](#)

- Prescribing pearls
- Drugs safety alerts
- The management of polypharmacy

12:25 – 12:45 [Home visits](#)

- Focusing on the clinical and holistic management of our more complex multimorbid patients with polypharmacy

12:45 – 13:00 [Practice Meeting](#)

- Systems management where we can share best practice or “GP hacks” to make life easier for us in primary care e.g. system templates and practice based protocols

13:00 – 13:05 [Chair’s close](#)

GPnotebook Shortcuts

The Management of Hyperglycaemia in those with Diabetes & Kidney Disease



CKD Stage (ml/min/1.73m ²)	Stages G1 & G2 eGFR >60	Stage G3a eGFR 45-59	Stage G3b eGFR 30-44	Stage G4 eGFR 15-30	Stage G5 eGFR <15
Metformin			Reduce dose to 500mg twice daily		
Sulfonylureas	Glidazide & glipizide preferred as metabolised in the liver		Increased risk of hypoglycaemia especially if eGFR <60. Reduce SU dose		
Repaglinide					
Acarbose	Avoid if eGFR <25				
Pioglitazone	Avoid in those on dialysis				
Alogliptin	Reduce to 12.5mg daily		Reduce to 6.25mg daily		
Linagliptin					
Saxagliptin	Reduce to 2.5mg daily. Avoid in those on dialysis				
Sitagliptin			Reduce to 50mg daily	Reduce to 25mg od	
Vildagliptin	Reduce to 50mg once daily if eGFR <50				
Canagliflozin			Do not initiate if eGFR <60; if eGFR later falls <60 reduce dose to 100mg & stop if <45		
Dapagliflozin					
Empagliflozin			Do not initiate if eGFR <60; if eGFR later falls <60, reduce dose to 10mg & stop if <45		
Dulaglutide					
Exenatide bid					
Exenatide qw	Not recommended if CrCl <50ml/min				
Liraglutide					
Lixisenatide					
Insulin	Increased risk of hypoglycaemia as kidney main route of insulin clearance				

● No dose adjustment required ● Dose adjustment recommended ● Not recommended / contraindicated

www.gpnotebookeducation.co.uk

[@GPnEducation](https://twitter.com/GPnEducation)

- GPnotebook Shortcuts are a series of quickly digestible bite-sized learnings to help us help our patients in primary care
- This GPnotebook Shortcut provides an up-to-date (as of November 2018) summary of dosing recommendations in renal impairment of commonly used hypoglycaemic agents in the UK

Eric



Age	52
History	Presented with general malaise
PMH	Nil
Blood pressure	134/88 mmHg
Lipid profile (mmol/L)	TC 5.4 TRG 3.7 HDL 0.9 LDL 2.9
BMI & Weight	33 kg/m ² Waist 102cm
LFTs (U/L)	ALT 62 (10-50), AST 63 (8-50), ALP 85 (40-125) GGT 65 (5-55) Bilirubin 17 (3-21)
HbA1c	42 mmol/mol
eGFR	>60 mL/min/1.73m ²
Current Medication	Nil
Social History	IT, non-smoker, social alcohol

What is the likely cause of his abnormal LFTs?

1. Viral hepatitis
2. Non-alcoholic fatty liver disease
3. Alcoholic liver disease
4. Autoimmune liver disease
5. Hepatocellular carcinoma

What is your next step with respect to his LFTs?

1. Lifestyle advice – weight loss and alcohol consumption
2. Refer GI/hepatology
3. Arrange routine liver USS
4. ELF
5. Ignore...



Abnormal LFTs & Management of NAFLD

- NICE NG49 2016, British Society of Gastroenterology 2018 & BMJ "Rational Testing" article 2018
- Mortality from liver disease has risen 4-fold since the 1970's...
- Main causes of liver disease:
 - Alcohol misuse
 - Chronic viral hepatitis
 - Obesity/metabolic syndrome which may lead to NAFLD
- If detected early, clinical interventions and lifestyle change may slow or stop progression of liver disease
 - Role of LFTs

Abnormal LFTs


- Mildly abnormal LFTs are very common!
 - Degree of abnormality does not always correlate with disease severity
 - LFTs often checked for unexplained or non-specific symptoms
 - 1:5 will have abnormal LFTs & most of these individuals will not have significant liver disease
 - BALLETS study BMJ Open 2013
 - n=1290 from primary care with abnormal LFTs and without **BMJ Open** disease
 - Only 2.5% (n=32) of people with abnormal LFTs had a specific disease of the liver
 - 40% of whole cohort had "fatty liver" on USS
 - 8 malignancies found
 - Repeating entire LFT panel in 1 month is ineffective!
 - ALT & ALP most associated with significant liver disease
 - GGT had a very high false positive rate but was sensitive
 - So, worth having a heuristic at hand to identify those with modifiable liver disease



Interpreting LFTs

- ALT is predominantly liver-specific and is sensitive indicator of liver injury e.g. viral hepatitis
- AST is not as liver-specific but is a more sensitive marker of liver injury particularly alcohol
- Isolated GGT difficult to interpret as raised by multiple factors
 - Alcohol, obesity & several drugs
 - However, GGT best predictor of mortality in established liver disease
- ALP found in liver (key biliary tract enzyme), bone and placenta
 - If raised ALP worth checking GGT – if GGT normal think “bone”, if GGT high think “liver”
- Isolated raised bilirubin often due to Gilbert’s syndrome but sometimes due to haemolysis
- Clotting and platelets can also be abnormal in advanced liver disease

Response to abnormal liver blood tests.



Philip N Newsome et al. Gut 2018;67:6-19

Diagnosis & Management of NAFLD

- Commonest liver disease in Western world
 - 25-30% of adults & 70-90% of those with obesity or T2D
 - Associated with increased risk of CVD & T2D
- NAFLD spans a spectrum of progressive pathological liver changes
 - Hepatic steatosis is an early manifestation
 - Steatohepatitis (NASH) is more serious and associated with fibrosis & cirrhosis
- Consider risk factors & check full liver screen
 - Abnormal ALT best predictor of NAFLD
- Liver USS recommended by BSG 2018

Diagnosis & Management of NAFLD

- NICE NG49 recommends an ELF test for those with NAFLD & Fibroscan for all heavy drinkers (>50 units weekly for men and >35 units for women)
 - Neither of these routinely available in primary care!
- BSG recommends use of NAFLD fibrosis score to aid management: www.nafldscore.com
- AST:ALT can be helpful; ALT should be higher than AST in early NAFLD
 - If ratio <1.0 suggests NAFLD with low risk of progression
 - If ratio >1.0 suggests more serious liver disease & higher risk of progression
 - If ratio >2.0 strongly suggestive of ALD
- Hepatology referral recommended for those at high risk of advanced fibrosis

Diagnosis & Management of NAFLD

- What can we do in primary care for those at lower risk of advanced fibrosis?
 - Assess CV risk using QRISK3-2018 <https://qrisk.org/three/> & consider statin
 - Actively manage any co-existing diabetes, hypertension and alcohol excess
 - Strongly encourage and facilitate weight loss where possible
 - Re-assess risk after 2-5 years depending on clinical risk and consider referral if:
 - AST:ALT ratio >1.0
 - LFTs >3x normal limits
 - Symptoms or signs of progression of liver disease
 - Any features of atypical disease

Eric



What is the likely cause of his abnormal LFTs?

Non-alcoholic fatty liver disease

What is your next step with respect to his LFTs?

Lifestyle advice – weight loss and alcohol consumption

Consider further investigation or referral as AST:ALT >1.0

Age	52
History	Presented with general malaise
PMH	Nil
Blood pressure	134/88 mmHg
Lipid profile (mmol/L)	TC 5.4 TRG 3.7 HDL 0.9 LDL 2.9
BMI & Weight	33 kg/m ² Waist 102cm
LFTs (U/L)	ALT 62 (10-50), AST 63 (8-50), ALP 85 (40-125) GGT 65 (5-55) Bilirubin 17 (3-21)
HbA1c	42 mmol/mol
eGFR	>60 mL/min/1.73m ²
Current Medication	Nil
Social History	IT, non-smoker, social alcohol



Emma



Age	49
History	Recently opportunistically diagnosed with T2D
PMH	None
Blood pressure	129/79 mmHg
Hba1c	58 mmol/mol
BMI & Weight	31 kg/m ²
Current Medication	Evening primrose oil
Social history	Teacher, non-smoker



“I read in the Daily Mail that I can reverse my diabetes – is this true?”

HOME GADGETS THAT SPY ON YOU FREE PULL OUT

Daily Mail
TUESDAY, SEPTEMBER 11, 2018 www.dailymail.co.uk 65p

Have they really killed Keeley? 10 BODYGUARD THEORIES THAT WILL HAVE YOU HOOKED PAGES 22-23

SOUP AND SHAKE DIET ON THE NHS TO REVERSE DIABETES
Radical treatment could help millions

DIABETICS will be given low-calorie liquid diets under radical plans to beat the disease. 1,000 diabetics hope their lives will be saved as the NHS trials the shake and soup diet. The trial will be set up in November. It is hoped the shake and soup diet will reverse the illness. If the trial succeeds, the treatment will be rolled out nationally. UK research has already found that a diet of 75 per cent carbohydrates on the diet can reverse diabetes in a trial. Details of the shake and soup diet will be set out in November. It is hoped on the shake and soup diet 1,000 diabetics will be reversed if patients lose enough weight. On the diet, they would consume between 600 and 800 calories a day, depending on the tolerance of the diabetics and receive three shakes a day. Many would lose four pounds very quickly after previously taking as many as 3,000 calories a day. The shake and soup diet was developed as

MORE lolly for £21m Holly as she bags M&S deal


SEE PAGE SEVEN

Diabetes Remission Clinical Trial (DiRECT)

- DiRECT published its 12 month results in the Lancet February 2018
 - Can intensive weight management in primary care with a low energy formula diet achieve remission of T2D?
- Study participants (n=306) were aged 20-65 who had been diagnosed with T2D within the previous 6 years with BMI 27-45 and not on insulin
- Intervention (n=150)
 - Withdrawal of antidiabetic & antihypertensive drugs
 - Total diet replacement with a low energy formula diet (around 850kcal daily)
 - Stepped food reintroduction
 - Structured support for long-term weight loss maintenance
- Remission defined as HbA1c <48mmol/mol after at least 2 months off all antidiabetic medication at 12 months

Diabetes Remission Clinical Trial

(DiRECT)



Diabetes Remission Clinical Trial (DiRECT)

- Other challenges:
 - Support required in primary care; nurse or dietitian in each intervention practice received 8 hours structured training
 - There is no international consensus on criteria for diabetes remission: DiRECT vs. ADA
 - Do not code “diabetes resolved” (Z12H), use instead “diabetes in remission” (Z10P) so remain on annual recall
 - These individuals may still experience macrovascular & microvascular complications of diabetes and therefore need continued monitoring
- Very low energy diets are not the panacea for the management of T2D

Emma




Age	49
History	Recently opportunistically diagnosed with T2D
PMH	None
Blood pressure	129/79 mmHg
Hba1c	58 mmol/mol
BMI & Weight	31 kg/m ²
Current Medication	Evening primrose oil
Social history	Teacher, non-smoker

“I read on the BBC website that I can reverse my diabetes – is this true?”



- A change of conversation is now required - T2D can be a progressive disease; there is opportunity to reverse it with significant weight loss
- Emma - you can reverse your diabetes if you lose over 15kg over the next 12 months

Laura



Age	47
History	Annual private health screen picks ++ blood on dipstick. Laura is asymptomatic
PMH	No PMH of note
Blood pressure	126/72 mmHg
eGFR	>60 mL/min/1.73m ²
Current Medication	Nil
Social history	Hedge fund manager. Non-smoker. Social alcohol

What is your next step?

1. Utter a barrage of expletives aimed mainly at the private GP who under took the health screening
 2. Repeat the dipstick urine test in 2-3 weeks
 3. Refer routinely to urology
 4. Refer urgently to urology
- There is no compelling evidence to support population screening for non-visible haematuria in asymptomatic people
 - Studies suggested 1-4% of those who screen positive for NVH will have serious underlying pathology such as bladder cancer
 - Common spurious causes include menstruation and physical exertion especially long distance running



Management of Asymptomatic Non-Visible Haematuria

- British Society of Urological Surgeons & Renal Association 2008 & BMJ
"Rational Testing" article 2014, NICE & Scottish cancer guidance 2015
- All those with persistent NVH require primary care follow-up to exclude progressive kidney disease
 - Persistent is defined as asymptomatic NVH that persists for at least 2 out of 3 samples, separated by 2-3 weeks
 - Assess baseline renal status – BP, U&Es & urinary ACR
- NB Individuals on aspirin, warfarin or DOACs should be managed in the same way as those not on these drugs

Laura



Age	50
History	Annual private health screen picks ++ blood on dipstick. Laura has no urinary symptoms
PMH	No PMH of note
Blood pressure	126/72 mmHg
eGFR	>60 mL/min/1.73m ²
Current Medication	Nil
Social history	Hedge fund manager. Non-smoker. Social alcohol

Do we need to confirm this result with microscopy?



- No. Microscopy only accurate on fresh samples of urine; red cell counts seen on microscopy reduce quickly with time
- We can ignore any trace of blood on dipstick; there must be at least 1+ blood on dipstick for NVH to be present
- It is of no significance if it is haemolysed or non-haemolysed
- If red cell casts are seen, this is pathognomic of glomerulonephritis

Laura



Age	50
History	Annual private health screen picks ++ blood on dipstick. Laura has no urinary symptoms
PMH	No PMH of note
Blood pressure	126/72 mmHg
eGFR	>60 mL/min/1.73m ²
Current Medication	Nil
Social history	Hedge fund manager. Non-smoker. Social alcohol

Laura hands in a repeat sample 3 weeks later which is also positive for blood. What do we do next?



- Laura requires further investigation of her baseline renal function
 - U&Es, BP & urinary ACR
- What we do next depends on the age of the patient
 - Those <40y with normal baseline renal function need annual primary care monitoring
 - » Refer renal if eGFR<60, ACR>30 or BP>140/90
 - Those >40y require referral to urology
 - » NICE 2015 cancer guidelines suggest an urgent referral if >60y & raised WCC. Scottish guidance suggests routine referral
 - There is no need to arrange primary care imaging

Laura



Age	50
History	Annual private health screen picks ++ blood on dipstick. Laura has no urinary symptoms
PMH	No PMH of note
Blood pressure	126/72 mmHg
eGFR	>60 mL/min/1.73m ²
Urine ACR	<3.5mg/mmol
Current Medication	Nil
Social history	Hedge fund manager. Non-smoker. Social alcohol

Laura's baseline renal function is normal and a routine cystoscopy did not reveal any underlying malignancy. What do we do next?



- Laura requires annual primary care monitoring of her baseline renal function for as long as her NVH persists
 - U&Es, BP & urinary ACR
- Refer renal if eGFR<60, ACR>30 or BP>140/90
- Laura should be informed to report any urological symptoms or visible haematuria which would trigger a referral to urology

Brodie



Age	4
History	Restless and snores loudly through the night. Irritable & hyperactive during the day
PMH	Nil
Weight	90 th centile
Examination	Alert, feral Normal facies Ears nad, turbinates a little swollen Throat - large tonsils not infected or inflamed
Social history	Only child, attends nursery, no concerns about developmental milestones

What is the likely underlying diagnosis?

1. Simple snoring
2. Allergic rhinitis
3. Obstructive sleep apnoea
4. Laryngeal hypertrophy
5. Attention-Deficit/Hyperactivity Disorder (ADHD)

What is your next step?

1. Refer paediatric dietitian
2. Refer paediatric ENT
3. Refer CAMHS
4. Reassure parents
5. Trial intranasal steroids



Obstructive Sleep Apnoea in Children

- BMJ "10-minute Consultation" 2017 & BJGP "Clinical Intelligence" 2017
- Affects 1-4% of children and can lead to cor pulmonale, RVH and systemic hypertension if untreated
- Uncomplicated OSA
 - Adenotonsillar hypertrophy in children with no other significant PMH
- Complicated OSA
 - Secondary to medical condition such as obesity, craniofacial abnormalities (e.g. cleft palate), Down's syndrome and neuromuscular disease (e.g. cerebral palsy,

Obstructive Sleep Apnoea in Children

- Presentation of paediatric OSA is different to OSA in adults
 - More likely to present with behavioural problems, poor attention and reduced academic performance rather than daytime sleepiness
- History
 - Night: Snoring, disturbed sleep, obstructive apnoeic episodes, secondary enuresis, parental concern
 - Day: Irritable or excessively tired during the day, mouth breather, nasal speech, developmental delay or behavioural problems
 - Symptoms of ADHD (25% of OSA) or poor school performance
- Examination
 - Growth, syndromic or craniofacial abnormalities, neck arching, mouth breathing or stertor, nasal obstruction, tongue & tonsil size, otitis media

Obstructive Sleep Apnoea in Children

Support for you Take action What we do [HELPLINE](#) [DONATE](#) [SEARCH](#) 


Obstructive sleep apnoea (OSA) is a breathing problem that happens when your child's asleep.

[Overview](#) [What is it?](#) [Causes](#) [Symptoms](#) [Diagnosis](#) [Treatment](#)



Children's lungs

- ▶ How lungs grow
- ▶ Risks
- ▶ Signs of problems
- ▶ After diagnosis



Your stories

[Read about the experiences of people like you.](#)



[Every night I watched my son stop breathing](#)

Milo was diagnosed with OSA aged 4. His mum Rebecca talks about his exhausting experience.



[Symptoms of OSA in children](#)

Learn about the common symptoms of OSA in children.



OSA
Obstructive sleep apnoea
What you need to know

[OSA leaflets and booklets](#)

View our collection of leaflets and resources.

“I have tonsillitis again – Dr Coxon usually gives me antibiotics”



Sarah J.



Age	30
History	Presents with severe sore throat last 3 days. No associated cough or cold symptoms, muscle aches or fever
PMH	History of recurrent sore throats
Current Medication	COCP
Examination	Apyrexial. Mild cervical lymphadenopathy Mild inflamed tonsils but no pus

What do you do next?

1. Tell her to go and see Dr Coxon
2. Offer her an immediate prescription of penicillin V for 10 days
3. Offer her an immediate prescription of penicillin V for 5 days
4. Offer her a delayed antibiotic prescription of penicillin V for 10 days
5. Offer her a delayed antibiotic prescription of penicillin V for 5 days

THANK YOU FOR LISTENING.
ANY QUESTIONS?



kevin@gpnotebook.co.uk



@GPnEducation @drkevinfernando
Kevin Fernando



www.gpnotebookeducation.co.uk





GP notebook Clinics





Mr Jonathon Pleat

BM BCh (Oxon), MA (Oxon), DPhil (Oxon), FRCS (Plast)

SPECIALITIES

Plastic Surgery, Cosmetic Surgery

YEAR OF FIRST QUALIFICATION

1995

LANGUAGES SPOKEN

English

WEBSITE

<http://www.scarteam.co.uk>

TELEPHONE

0117 9064870

EMAIL

Bristol.enquiries@nuffieldhealth.com

GMC NUMBER

4213433

FAX

01179 254909



North Bristol NHS Trust

Search

- About Us
- Our Hospitals
- Our Services**
- Patients & Carers
- Careers
- Clinicians
- Research
- Education
- Support Us

You are here: Home / Our Services / A-Z of Consultants / Mr Jonathon Pleat

Mr Jonathon Pleat - Plastic Surgery

Mr Jonathon Pleat - Plastic Surgery

GMC number: 4213433

Year of first qualification: 1995, Oxford University

Specialty: Plastic and Reconstructive Surgery

Clinical interest: Skin cancer, burns, scarring and general plastic surgery

Secretary: Cherie Taylor

Telephone: 0117 4147415

Mr Jon Pleat is a plastic surgeon with a general interest in burns, scarring and reconstructive surgery.

He trained in Oxford, Bristol and plastic surgery services within the UK and abroad.

He is a Director of Research for the burns and wound healing charity, Restore. His research interests encompass first aid, wound healing, scarring, burn outcome and cell culture for skin resurfacing.

He collaborates with multiple research groups at the Universities of Bristol, Oxford, Bath and The University of the West of England.

Mr Pleat was one of the founding editors of the national primary care resource, GPNotebook.

- Related links**
- » Plastic Surgery
 - » Plastics - For Clinicians

General Paediatrics staff

Dr Ian Wacogne

Consultant in General Paediatrics / Assistant Chief Medical Officer for Information Technology

As well as being a highly experienced General Paediatrics Consultant Ian is our Assistant Chief Medical Officer for Information Technology. He plays a key role in making sure our IT developments will give our staff the freedom to do their jobs better than ever in the coming years.

Ian loves his job, and the fact that it keeps him stimulated, excited, frustrated, and thinking all of the time. Despite his years of experience, he is always ready to learn and looks forward to the new challenges that each day brings.



Contact

0121 333 8167

ianwacogne@nhs.net

Related services

- [General Paediatrics](#)

More about me

Ian is a keen cyclist and likes to ride his bike until he can't ride it any further before turning around and riding it home again.



Tweets 16.8K Following 530 Followers 1,470 Likes 13.1K

Ian Wacogne

@ian_wac


Husband, father, paediatrician, editor, associate chief medical officer. Ride a bike too. Take your pick. Don't like these opinions? I've got plenty of others.

Birmingham, UK

wacogne.wordpress.com

Joined January 2010

652 Photos and videos



Tweets Tweets & replies Media

Pinned Tweet



Ian Wacogne @ian_wac · 14 Dec 2018
In our cycle sheds at work this evening...

#LoveCyclingWM



Have an account?

Phone, email, or username

Password

Remember me · [Forgot password?](#)

Log in

New to Twitter?

Sign up

Sign up

You may also like · Refresh

Ed and Prac from ADC @ArchivesEandP

Mary Salama @whosalama

Vin Diwakar @Vin_Diwakar

Dr Steven Young-Min

Consultant Rheumatologist
BA Hons (Oxon), BMBCh, PhD, FRCP



Contact us ↑

Practising at

Practising at

Treatments

Spire Portsmouth Hospital

Professional profile

Practising at

Treatments

Professional profile

Qualifications and professional memberships

Current NHS posts

Professional profile

I am the clinical lead for the osteoporosis and ankylosing spondylitis services. My practise however is diverse and spans the entire range of rheumatology from localised back or soft-tissue rheumatism to multisystem disease.

I perform a wide range of procedures including ultrasound guided and non-guided injections, as well as suprascapular nerve blocks and caudal epidurals. In addition to scientific papers, I am the author of the bone health guidelines for Portsmouth and south-east Hampshire and one of the founding authors of a popular on-line resource for GPs called gpnotebook.co.uk.

I am a frequent speaker at local patient conferences and is a tutor for the Wessex rheumatology ultrasound group. On a more national stage, I give lectures for the British Medical Journal master classes in musculoskeletal medicine and rheumatology and run injection courses for the Royal College of General Practitioners.

I have been a consultant rheumatologist in Portsmouth since 2006. I was born in London, from Mauritian Chinese parents, I qualified from Oxford University Medical School in 1994 and undertook my junior rotations in Oxford, Bath and Newcastle-upon-Tyne.

I trained in rheumatology in the north-east of England, where I was awarded an Arthritis Research UK Clinical Research Fellowship. My PhD research was focused on early rheumatoid arthritis and biochemical markers of rheumatic disease.

Contact us



Primary Care Digital Transformation - Regional Conference Midlands and East Region | 19 April 2018 Agenda



Morning session

Exhibition | The NHS teams and clinical system suppliers will be available through the morning to offer advice.

Time slot	Stream 1 - GP Online services	speakers	Stream 2 - Empower the person	speakers
09:30 – 10:00	Tea/coffee on arrival			
10:00	Welcome	Paul Fleming Regional Head of Digital Technology, NHS England		
10:10	GP online services	Emma Halliday Implementation Lead, NHS England	Empower the person (EtP) An overview of EtP pillar and roadmap of current and forthcoming digital services, information and tools for patients and citizens, with a focus on:	Phillipa-Rose Hodgson Kristen Allin Leanne Summers Digital Experience Team, NHS England
10:40	Nursing appointments and making the most of online appointments	Emma Halliday Implementation Lead, NHS England	<ul style="list-style-type: none"> National NHS Online app rollout Using NHS WiFi in primary care Transforming NHS Choices Apps and standards in primary care Widening digital inclusion to reduce health inequalities Questions and answers 	
11:10 – 11:30	Break			
11:30	Test results sharing them with patients	Dr Clive Prince Digital Clinical Champion, NHS England	PPG session Involving your PPG in promoting to patients	Karen Johnson Programme Delivery Manager, NHS England
12:00	Patient centred care and online services	Dr Clive Prince Digital Clinical Champion, NHS England	Online Consultations	Nikki Hinchley Digital Primary Care (GPIT) Programme Lead/SME
12:30 – 13:30	Lunch, Exhibition and Networking			

Dr Damian Crowther

Cambridge Neuroscience

About us

- > [Governance](#)
- > [Neuroscience in Cambridge](#)
- > [Introduction by Andrew Huxley](#)
- > [A short history](#)
- > [Privacy Policy](#)

Research and Collaboration

- > [Research themes](#)
- > [Collaboration in action](#)
- > [Publications](#)

Directory

- > [Search](#)
- > [Principal investigators](#)
- > [All members](#)



University position

Director R&D, AstraZeneca Neuroscience
IMED

Departments

[Department of Genetics](#) and [Department of Medicine](#)

Institutes

AstraZeneca Neuroscience IMED

Email

Interests

The neuroscience group at AstraZeneca has particular interests in neurodegeneration, neuropsychiatry and pain. We are a highly collaborative group and keen to work productively with the Cambridge neuroscience community. More details at: www.azneuro.com

Research Focus

Keywords

Alzheimer's Disease
dementia
animal model
protein aggregation
genetics

Clinical conditions

Alzheimer's disease
Cognitive impairment

Equipment

Behavioural analysis



Damian C. Crowther

University of Cambridge
Verified email at cam.ac.uk - [Homepage](#)
[neurodegeneration](#)


FOLLOW

[GET MY OWN PROFILE](#)

TITLE	CITED BY	YEAR
Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease DC Crowther, KJ Kinghorn, E Miranda, R Page, JA Curry, FAI Duthie, ... Neuroscience 132 (1), 123-135	325	2005
Endoplasmic reticulum dysfunction in neurological disease BD Roussel, AJ Kruppa, E Miranda, DC Crowther, DA Lomas, ... The Lancet Neurology 12 (1), 105-118	289	2013
ANS binding reveals common features of cytotoxic amyloid species B Bolognesi, JR Kumita, TP Barros, EK Esbjorner, LM Luheshi, ... ACS chemical biology 5 (8), 735-740	243	2010
Systematic in vivo analysis of the intrinsic determinants of amyloid β pathogenicity LM Luheshi, GG Tartaglia, AC Brorsson, AP Pawar, IE Watson, F Chiti, ... PLoS biology 5 (11), e290	187	2007

Cited by [VIEW ALL](#)

	All	Since 2014
Citations	3499	1874
h-index	31	23
i10-index	58	49





Emergency Helicopter Medics | Tern TV for More 4 | Episode 5 Clip

8 months ago | More

ARTEUS POST PRODUCTION PRO + Follow

More from ARTEUS POST PRODUCTION

Autoplay next video



Emergency Helico...
ARTEUS POST PRODUCTION



Emergency Helico...